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Amine oxidases (AOs) are ubiquitous enzymes involved in the metabolism of biogenic 
amines. Copper AOs (Cu-AOs) catalyze the oxidative deamination of primary amine 
groups of several biogenic amines, such as putrescine, cadaverine, and histamine. In the 
present review, the effects of a plant amine oxidase (Cu-AO, histaminase, EC1.4.3.6) 
purified from pea seedlings in the modulation of IgE-mediated allergic reactions, and in 
the prevention of cardiac and splachnic postischemic reperfusion damage are reported.  
KEYWORDS: pea seedling histaminase, copper amine oxidases, inflammation, cardiac 
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OVERVIEW 
Biochemistry of Amine Oxidases 
Amine oxidases (AOs) are a broad class of Cu- or FAD-containing enzymes (Cu- and FAD-AOs) 
distributed among all living organisms, which are able to oxidize biogenic amines to hydrogen peroxide 
(H2O2) and aldehydes. Their widespread occurrence accounts for an undoubtedly relevant function in 
biogenic amine metabolism. AOs are heterogeneous in structure, catalytic mechanisms, and mode of 
substrate oxidation. Mono, di-, and polyamines are oxidatively deaminated by AOs in a reaction 
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consuming O2 and H2O, and producing the corresponding aldehyde, the removed amine moiety, and H2O2 
in stoichometric amounts according to the following reaction: 
H2NH2 + O2 + H2O     →      RCHO + NH3 + H2O2 
Cu-AO contains a second cofactor, topaquinone (TPQ)[1], which is produced by post-translational 
oxidation of a tyrosine residue catalyzed by the same Cu2+[2,3]. The second group of AOs contains FAD 
as a cofactor and includes cytosolic polyamine oxidase (PAO) and mitochondrial monoamine oxidase 
(MAO). PAO participates in the interconversion metabolism of polyamines (PAs). MAOs are tightly 
bound to the outer mitochondrial membrane and occur in two isoforms, named A and B. In general, 
MAOs oxidize primary arylalkyl amines and are widely distributed among eukaryotes. In the present 
review, some physiopathological aspects of Cu-AO/histaminase (diamine oxidase, DAO) and the possible 
therapeutic applications of these enzymes will be discussed. 
Copper Amine Oxidases and Their Involvement in Physiology and 
Pathophysiology 
Cu-AOs are dimeric proteins, each subunit weighing about 70–90 kDa, with 33 fully conserved residues 
near the catalytic site. The active site, consisting of one Cu2+ and one TPQ connected by a water 
molecule, is located inside each subunit and is connected with the outer aqueous phase through a 
hydrophobic channel. In the last few years, the structure of several Cu-AOs has been revealed by means 
of X-ray chromatography and gene cloning[4]. The crystal structure of bovine serum AOs (BSAOs) was 
recently published[5]. 
A number of diverse physiological functions have been ascribed to AOs, although their exact role and 
biological activity are not completely understood. These enzymes are involved in different metabolic 
processes depending on the action of their substrates and reaction products. There is ample evidence that 
polyamines, H2O2, and aldehydes are of pivotal physiological relevance in cell proliferation, 
differentiation, and death[6]. For example, depending on its concentration, H2O2 can either impair cell 
growth and proliferation, or regulate gene expression and transduction of cell signaling[7]. Moreover, 
injection of as little as 0.3 units of pig kidney diamine oxidase (pkDAO), immobilized on concanavalin 
A-Sepharose, into the peritoneal cavity of Swiss mice 24 h after transplantation of neoplastic Ehrlich 
ascite cells, resulted in a strong inhibition of intraperitoneal tumor cell growth[8]. Of note, these cells 
contain a considerable amount of polyamine (PA), which appears to be oxidized by DAO. In this context, 
99% inhibition of Ehrlich ascite cell proliferation was observed in the presence of oxidized spermine, 
whereas spermine had no effect[9]. Overall, these results may suggest a possible use of AOs in anticancer 
therapy[10]. As a matter of fact, BSAO, added to the incubation mixture of cultured Hamster fibroblasts 
in the presence of added polyamines, has a cytotoxic effect[11]. Cu-AOs may act by post-translational 
modification of proteins[12]; for instance, Cu-BSAO can mediate the oxidation of polypeptide amino 
groups, as occurs with synthetic polylysine, as well as endogenous lisozyme and ribonuclease A. At the 
cellular level, Cu-BSAO has been observed to modulate the electric properties of ion channels in 
neuroblastoma cells, thereby increasing the current of the K+ channels[13]. At the organ level, Cu-BSAO 
was found to have a protective effect on cardiac function, as it exerts antiarrhythmic effects on isolated rat 
hearts subjected to regional ischemia and reperfusion[14]. This effect could be due, at least in part, to its 
antioxidant action against electrolysis-induced generation of oxygen free radicals and their by-products. 
Cu-AOs are likely involved in leukocyte adhesion and extravasation. Salmi and Jalkanen[15] 
demonstrated that VAP-1, a cell surface endothelial glycoprotein, is actually a Cu-AO. This enzyme, 
which is sensitive to semicarbazide-specific inhibitors of AO is able to metabolize substrates like 
benzylamine and methylamine, and has striking molecular similarities to Cu-BSAO[16]. This enzyme 
exerts catalytic activity against plasma membrane–bound amino groups, such as the N-terminus of 
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proteins, NH2-containing amino acid residues, amino carbohydrates, etc. Overproduction of Cu-AOs 
appears to be dangerous, as observed in diabetes, heart attack, ischemia, and cataract. Cu-AO activity is 
increased in diabetes, particularly in diabetic patients with vascular complications, probably due to the 
production of endogenous cytotoxic compounds[17]. Transgenic diabetic mice showed an increase in Cu-
AO activity in serum, kidney, and adipose tissue. This increased Cu-AO activity in diabetes is probably 
dependent on post-transcriptional modification or activation of prestored inactive enzyme molecules. 
These results, and in particular the role of diabetic vascular dysfunction on the negative effects of Cu-AO, 
are in agreement with the results of Ucar et al.[18]. They reported that elevated Cu-AO activity is 
correlated with H2O2 production in lungs with ischemia-reperfusion injury. Of note, in this model, 
ischemic preconditioning associated with Cu-AOs inhibition has a protective effect. In humans, 
enhancement of DAO activity has been directly related to cataract formation[19]. Lens proteins were 
modified by H2O2 production and/or post-translational modification due to Cu-AO activity[20]. In this 
case, FAD-MAO and PAO do not appear to be appreciably involved. 
It should be pointed out that a proper concentration of Cu-AO and reactive oxygen species (ROS)–
scavenging enzymes, such as superoxide dismutase and glutathione peroxidase, are crucial to explaining 
the beneficial/dangerous effects of copper Cu-AOs and in particular of histaminase. In this context, the 
identity of DAO and histaminase should be pointed out[21]. This enzyme shows a protective effect 
against various diseases. For example, it has been localized in decidual cells of human placenta[22], 
where it may be a local defense mechanism against noxious products of fetal origin, such as putrescine 
and PAs, which are produced in large amounts by tissues with a high proliferation rate[23]. Localization 
of DAO in kidney tubular cells suggests a role of DAO in regulating the concentration of histamine and 
other biogenic amines in blood and urine[24].  
Other enzymes of the class of DAOs are the semicarbazide-sensitive AOs with affinity for 
benzylamine (Bz-SSAOs), or benzylamine oxidase, which are inhibited by carbonyl reagents and catalyze 
the oxidative deamination of several monoamines[25]. Benzylamine oxidase is a widely distributed 
enzyme, for it has been detected in various tissues of many animal species, including humans[26]; this 
enzyme can also contribute to histamine catabolism. 
Role of Diamine Oxidases in Anaphylaxis 
Histamine plays a fundamental role in anaphylaxis, and histaminase is involved in allergic and 
pseudoallergic reactions. At variance with other metabolic pathways, histaminase activity is not directly 
up-regulated by endogenously released histamine. For instance, plasma histaminase activity increases in 
anaphylactic shock, but is not induced by released histamine, since it does not occur on histamine 
injection[27]. In some cases, histaminase levels may be intrinsically low and its activity further decreased 
by exogenous histamine, thereby predisposing to anaphylactic reactions. In a previous study, pigs were 
treated with 60 mg histamine. Half of the animals had histaminase inhibited by aminoguanidine and 
underwent marked elevation of plasma histamine (up to 160 μg/ml) associated with severe anaphylactic 
symptoms (e.g., hypotension, flushing, vomiting), causing some of them to die[28].  
Enhanced histamine levels in humans may be related to many factors, endogenous or exogenous. 
Food-induced histaminosis was described by Sattler et al.[29] as the result of high histamine content or 
histamine releasers in food. The first symptom of excess histamine intake and/or release is increased 
gastric secretion, occurring at plasma histamine levels of about 2 μg/ml. Tachycardia and headache may 
appear at 5 μg/ml and hypotension at 6–8 μg/ml[30]. The amount of histamine in food varies widely, 
commonly ranging from 0.16 to 23 μg/g[31]. The largest amounts of histamine and tyramine, which have 
similar vasoactive properties, are found in fermented foods, such as cheese, red wine, tinned fish, fish 
sauces, sauerkrauts, tuna fish, cured pork, and sausages[32]. The histamine content of French cheeses 
may even reach values higher than 800 μg/g, thus causing toxic symptoms. High levels of histamine have 
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been detected in Oriental food, accounting for the so-called Chinese restaurant syndrome[33]. Chemical 
de novo formation of amines may also occur during normal cooking and storage[34].  
It should be pointed out that many commonly used drugs are DAO inhibitors and approximately 20% 
of the general population take these drugs[1]. Other factors (alcohol, spoiled food, etc.) can also block 
DAO activity. The concept of pseudoallergic reactions to food, or false food allergies, was first suggested 
by Dukor et al. in 1980[35]. The abnormal intake of biogenic amines like histamine and tyramine is one 
of the major mechanisms involved[30]. The main clinical symptoms are fall in blood pressure, 
angioedema, vasomotor headaches, defects of intestinal functions, cutaneous and respiratory symptoms, 
etc. Juhlin[36] suggests that authentic food allergy accounts for less than 3% of the cases of chronic 
urticaria, whereas false food allergies are involved in 40% of all cases. Abnormal intestinal permeability 
to histamine, either spontaneous or caused by irritant substances (e.g., alcohol, aspirin), could account for 
pseudoallergic reactions to food when symptoms arise after intake of abundant histamine-rich food. High 
levels of histamine may also derive from bacterial flora of the colon[37], especially in subjects with 
colonic dysmicrobism due to excessive intake of foods rich in cellulose and starch. Histamine of bacterial 
origin passes easily through the intestinal mucosa irritated by organic acids generated by 
fermentation[30].  
Besides excess histamine, other histamine-dependent mechanisms of pseudoallergic reactions to food 
may include changes in the activity of histamine-degrading enzymes. A drop in histaminase and MAO B 
was found in patients with atopic dermatitis[38]. Histaminase may also be inhibited by food toxins, 
sodium nitrite, curarizing agents, antibiotics (i.e., clavulanic acid), and viral hepatitis[30,39,40]. Reduced 
DAO activity and histamine catabolism seem to be involved in bronchoconstriction episodes occurring 
after intake of red wine or histamine-rich food[41]. Of note, intestinal DAO is thought to be required for 
clearance of diamine and putrescine[42]. Overall, the above studies indicate enteral histaminosis resulting 
from dysfunctional metabolism of endogenous or exogenous histamine as a major cause of food 
intolerance[43]. 
Elevated mucosal histamine content and secretion were observed in the gut of patients with allergic 
enteropathy, as well as in women with Crohn’s disease and ulcerative colitis[44,45]. In particular, 
evidence has been offered that mast cell–derived inflammatory mediators, including histamine, play a 
major pathogenic role in these diseases. Fogel et al.[46,47], using a model of ulcerative colitis in rats, 
demonstrated an overall improvement and reduction of the local inflammatory reaction after treatment 
with DAO from pig kidney immobilized on concanavalin A sepharose[46,47]. In particular, 
histopathologic changes in the colon of DAO-pretreated rats were markedly blunted, as were plasma 
ceruloplasmin activity and tissue myeloperoxidase[47]. These studies highlight the pivotal role of 
histamine in inflammatory bowel diseases, as well as the role of histaminase in controlling the levels of 
histamine in tissues and blood.  
When considered altogether, the above findings support the concept of a possible therapeutic use of 
plant-derived histaminase, characterized by high specific activity and ability to degrade various biogenic 
amines, including histamine and polyamines, for allergic and pseudoallergic diseases, as better discussed 
below. 
Plant-Derived Diamine Oxidase 
Plant DAO (Cu-AO; histaminase; EC 1.4.3.6) is physiologically involved in oxidative deamination of 
various biogenic amines to the corresponding amino-aldehydes. Production of H2O2 on amine degradation 
has been correlated with oxidative burst, cell death, as well as peroxidase-mediated lignification, 
suberization, and cell wall polymer cross-linking occurring during ontogenesis and defense 
responses[48,49]. DAO is the most abundant soluble protein detected in the extracellular fluids from 
Fabaceae, in particular, pea (Pisum sativum), lentil (Lens culinaris), and chickpea (Cicer arietinum) 
seedlings[50]. 
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Plant DAOs (histaminase) differ from the mammalian and prokaryotic enzymes in a number of 
peculiar features, mainly high turnover rate of catalysis, high binding affinity for histamine, and high 
chemical stability. Moreover, this enzyme can be isolated to a high degree of purity with two simple and 
inexpensive chromatographic steps. Recently, an international Patent (n. PCT/EP01/13770) has been 
taken by some researchers of our group for a drug based on plant-derived histaminase for the treatment of 
histamine-mediated diseases, such as cardiac anaphylaxis, allergic asthma, allergic and septic shock, 
urticaria, rhinitis, and conjunctivitis. The main sources of histaminase are etiolated seedlings of 
leguminous plants, such as P. sativum, L. culinaris, C. arietinum, and Latirus sativus, where this enzyme 
is present in high concentrations, up to 4% of total protein content. Despite the promising 
pharmacological potential of plant DAOs, their actual therapeutic use is limited by their immunogenicity 
and short half-life in blood. To overcome these problems, purified wild pea DAO has been modified by 
binding to polyethylene glycol (PEG), a polymer that masks the protein surface, giving rise to a semi-
synthetic derivative with decreased immunogenicity and catabolism, resulting in a prolonged half-life. In 
particular, animal studies have shown that PEGylation with a 20-kDa branched polymer totally eliminates 
DAO immunogenicity as judged by determination of IgM and IgG raised against the native enzyme, and 
causes a marked prolongation of detectable DAO levels in blood, thus markedly improving its 
pharmacokinetic profile. Of note, PEGylation did not interfere with DAO biological activity[51]. These 
findings offer good odds for the use of DAO/histaminase as a novel therapeutic approach to histamine-
related disorders. To validate this assumption, it is useful to review the current studies on pea seedling 
histaminase applied to animal models of anaphylactic and inflammatory diseases. 
PLANT DIAMINE OXIDASE/HISTAMINASE MODULATES ALLERGIC 
ANAPHYLACTIC RESPONSE IN THE GUINEA PIG 
The massive release of histamine from tissue mast cells elicited by the cross-linking of antigen with IgE 
bound to FCε receptors at the cell surface is considered the paramount event in type-I allergic reaction. 
The most commonly used experimental animal models of type-I allergic reaction encompass cardiac 
anaphylaxis ex vivo and asthma-like reaction in sensitized guinea pigs in vivo. Both these models have 
been used to investigate the therapeutic potential of pea seedling DAO. 
Protective Effect of Plant Histaminase on Cardiac Anaphylaxis 
It is well known that histamine, one of the major mediators implicated in anaphylactic reactions, is 
released from heart slices and perfused hearts of sensitized guinea pigs on antigen challenge[52]. pkDAO 
has been demonstrated to have antihistaminic activity in vivo and a protective role in guinea pig 
anaphylactic shock[53]. Recently, we have investigated this issue by studying the effect of purified pea 
seedling histaminase[54], both free and immobilized on CNBr-Sepharose[55], in active cardiac 
anaphylaxis[56]. Briefly, guinea pigs were sensitized by repeated intraperitoneal injections of ovalbumin 
(OA) and, 18–25 days later, they were killed and the heart removed and perfused ex vivo in a Langendorff 
apparatus, which allows an accurate determination of the main cardiac functional parameters, namely 
heart rate, contraction strength, and coronary flow. Challenge with OA to the isolated hearts induced 
typical histamine-related changes in cardiac function. These changes were (1) transient increase followed 
by long-lasting reduction of myocardial contractility, (2) increased heart rate and occurrence of severe 
arrhythmias, (3) transient, marked reduction in the coronary flow followed by a less-pronounced, long-
lasting phase of coronary constriction. In basal conditions, histamine content in the perfusates was low 
and, noteworthy, remained unchanged on addition of pea seedling histaminase. Histamine was released in 
the perfusates mostly during the first 5 min after OA challenge, whereas its levels returned close to the 
basal, prechallenge values after 30 min (Fig. 1). When OA challenge was performed in the presence of 
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free or immobilized histaminase (4 IU/ml) the positive inotropic and chronotropic response to OA was 
fully blocked, including a dramatic decrease in the occurrence of ventricular tachyarrhythmias, and in the 
levels of histamine in the perfusates (Fig. 1).  
 
FIGURE 1. Histamine release in the perfusates from untreated control hearts (•) and 
from hearts perfused with free (?) or immobilized (Δ) histaminase (4 IU/ml). Data 
are expressed as mean ± SEM of eight experiments.  
Cardiac mast cell granule content, evaluated by computer-aided densitometry on histological sections 
stained with a heparin-specific dye, was markedly decreased by OA challenge. As expected, none of the 
two assayed histaminase preparations reduced mast cell degranulation in response to the allergen.  
The fact that histaminase does not produce any inhibitory, chromoglycate-like effect on anaphylactic 
degranulation of mast cells is strengthened by the finding that the depletion of cardiac histamine produced 
by OA was the same in the absence or presence of histaminase treatment. Altogether, these observations 
suggest that the observed decrease in the anaphylactic reaction of the isolated, perfused guinea pig hearts 
in response to OA is chiefly dependent on the inactivation of endogenously released histamine by 
histaminase, both free and immobilized.  
It is well known that cyclic nucleotides and tissue Ca2+ levels play a key role as intracellular effectors 
in type-I anaphylactic reactions[57]. In the current cardiac anaphylaxis model[56], OA challenge caused a 
slight decrease in cardiac cGMP and increase in tissue Ca2+ levels, both effects prevented by histaminase 
treatment (Fig. 2A and B). 
The mechanisms underlying these effects of histaminase on tissue cGMP and Ca2+ remain a matter of 
speculation. Likely, this is not a direct effect of this enzyme, but may result from the interaction with the 
nitric oxide (NO) generation system, as NO can increase cardiac cGMP levels and decrease tissue Ca2+ 
concentrations[58]. In fact, in control hearts, OA evoked a significant increase in the amount of nitrites, 
the stable oxidation products of NO, in the perfusates. It is notable that both free and immobilized 
histaminase significantly increased the amount of nitrites in the perfusates in the last phase of the 
anaphylactic reaction. Moreover, the two enzymes were able to significantly increase cardiac NO 
synthase activity[56]. 
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FIGURE 2. Tissue levels of cGMP (A) and calcium (B) in control hearts (a), hearts after OA challenge (b), and after OA 
challenge on perfusion with free (c) or immobilized (d) histaminase (4 IU/ml). Data are expressed as mean ± SEM of eight 
experiments.  
Protective Effect of Plant Histaminase on Allergic Asthma-Like Reaction 
Allergic asthma is a major respiratory disease with a markedly increasing morbidity worldwide. Despite 
decades of research, its very complex, interwoven mechanisms are neither completely unveiled nor 
understood. Nevertheless, there is general agreement among basic and clinical scientists that histamine is 
a crucial mediator of inflammation and bronchospasm, two key features of allergic asthma[59]. On this 
ground, we carried out an experimental study to evaluate the effects of histaminase, free or immobilized, 
on asthma-like reaction induced in OA-sensitized guinea pigs by aerosolic exposure to the allergen. This 
animal model is known to reproduce respiratory abnormalities, airway hyper-responsiveness, and 
leukocyte lung infiltration resembling the functional and histopathologic hallmarks of human allergic 
asthma[60,61]. 
Histaminase (DAO, EC 1.4.3.6), free or immobilized on BrCN-Sepharose, 20 μg in 500 μl saline, was 
injected intraperitoneally and then tracked in blood, lung, and liver tissue to define its pharmacokinetic 
profile. Plasma histaminase levels were higher in the animals treated with free enzyme than in those 
treated with the immobilized one; as expected, no detectable enzyme was found in untreated animals. On 
the other hand, higher amounts of histaminase were found in lung and liver tissue from animals treated 
with the immobilized enzyme than in those treated with the free enzyme[60]. It was somewhat surprising 
that different amounts of histaminase were found in different organs and in blood on administration of the 
enzyme as free substance or BrCN-Sepharose–immobilized molecule. One possible explanation for the 
lower levels of immobilized histaminase in blood may be that BrCN-Sepharose used as the vehicle was 
not cross-linked, and thus tended to melt at body temperature. The unexpected, higher amounts of 
immobilized rather than free histaminase in lung and liver can be ascribed to the fact that homing of the 
enzyme conjugate in those organs may be facilitated by the presence of galactose units in the molecule of 
the Sepharose vehicle. 
Challenge of sensitized guinea pigs with aerosolized OA resulted in severe abnormalities in their 
respiratory pattern, consisting of reduced latency time for the appearance of cough, increased cough severity, 
and increased occurrence of dyspnea and gasping (Fig. 3A and B), indicating the onset of respiratory failure. 
As expected, OA challenge caused no respiratory abnormalities in the nonsensitized guinea pigs used as 
negative controls. Pretreatment with free or immobilized histaminase, either given intraperitoneally at the 
noted dose of 20 μg i.p., or administered as aerosol solution, 4 μg/ml (flow rate 0.5 ml/min, corresponding 
to a total dose of 0.8 IU of the enzyme), resulted in a marked reduction of breathing  
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FIGURE 3. Effects of CNB2-Sepharose 6MB immobilized histaminase (20 μg, given 
intraperitoneally 3 h before OA, or 4 μg/ml, given by aerosol 30 min before OA) on cough latency 
(A) and cough severity score (B) induced by OA challenge in sensitized guinea pigs. Data are 
expressed as box plot of 12 experiments; block lines represent median values, boxes represent 
interquartile range, whiskers represent extreme values. 
abnormalities and prevention of respiratory failure (Fig. 3A and B). The maximal protective effects were 
observed when the enzyme was given by aerosol 30 min before or together with OA challenge (Fig. 3A 
and B) 
Histaminase treatment also prevented the histopathological lung changes induced by OA challenge. 
Macroscopic examination of the lungs of the sensitized, OA-challenged guinea pigs showed marked 
swelling of the pulmonary lobes due to peripheral airway obstruction and air entrapment. Lung inflation 
was not observed on treatment with histaminase. Accordingly, light microscopic and morphometric 
analysis of lung tissue from the sensitized guinea pigs challenged with OA showed a marked, significant 
constriction of intrapulmonary bronchi and dilation of respiratory air spaces. On the other hand, 
histaminase treatment of the OA-challenged animals resulted in no appreciable signs of intrapulmonary 
bronchial constriction and respiratory air space dilation (Fig. 4 A–D). 
As observed in the cardiac anaphylaxis model, mast cell granule content was markedly reduced in the 
sensitized guinea pigs challenged with OA, regardless of pretreatment with histaminase at any 
concentration and administration route, as compared with the nonsensitized negative controls. This 
finding further supports the notion that histaminase does not have any stabilizing, chromoglycate-like 
effect on allergen-induced granule release by lung mast cells. 
Finally, histaminase treatment reduced lung inflammatory tissue injury, namely leukocyte infiltration 
and oxygen free radical generation. In fact, both free and immobilized histaminase markedly and 
significantly reduced myeloperoxidase (MPO) activity, an indication of tissue leukocyte infiltration, and 
malonyldialdehyde (MDA) production, an indication of peroxidation of cell membrane lipids by ROS, 
which were markedly increased in the lung tissue from sensitized, OA-challenged guinea pigs not given  
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FIGURE 4. Representative lung tissue micrographs from (A) naïve guinea pig, (B) sensitized guinea 
pig undergoing OA aerosol, (C) sensitized guinea pig pretreated with aerosolic histaminase 30 min 
before OA aerosol, (D) sensitized guinea pig treated intraperitoneally with histaminase 3 h before 
OA aerosol. Hematoxylin & eosin; bar = 200 μm.  
this enzyme compared to the unsensitized control animals. No difference in efficacy was noted between 
free and immobilized histaminase. 
PLANT DIAMINE OXIDASE/HISTAMINASE HAS A PROTECTIVE EFFECT AGAINST 
ISCHAEMIA-REPERFUSION INJURY 
Besides its pivotal involvement in anaphylaxis and allergic reaction, histamine plays a role in 
exacerbation of inflammatory tissue damage, as many proinflammatory mediators, such as prostanoids 
and cytokines, are potent mast cell activators[62]. In particular, histamine has been found to contribute to 
endothelial dysfunction, hampering of blood-tissue exchange, and functional tissue impairment occurring 
in organs undergoing ischemia and reperfusion[63]. On these grounds, we hypothesized that pea seedling 
histaminase could effectively blunt the adverse effects of ischemia-reperfusion and we carried out 
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experiments on specific animal models to prove this assumption. The results obtained have met our 
expectations, as summarized below. 
Protective Effect of Plant Histaminase in a Rat In Vivo Model of Cardiac Ischemia-
Reperfusion 
The heart is particularly susceptible to tissue damage by several key agents involved in the 
pathophysiological mechanisms of ischemia-reperfusion, such as ROS, histamine, and NO[64,65,66]. A 
close relationship between histamine, acting as a pro-oxidant, and ROS was observed in patients with 
coronary heart disease[67]. In turn, histamine release by mast cells is amplified by excess superoxide 
generation and concurrent decrease in local NO amounts, due to the fact that superoxide and NO react 
promptly, giving rise to harmful peroxynitrite[68]. Moreover, histamine per se may induce a spasm of the 
coronary vessels, thereby causing or worsening acute coronary insufficiency and myocardial 
ischemia[63]. During ischemia, the increase in histamine levels in the coronary sinus is paralleled by the 
occurrence and severity of ventricular arrhythmias[69]. To assess whether pea seedling histaminase has 
cardioprotective effects against postischemic reperfusion damage, we used a typical in vivo model in the 
rat. Briefly, anesthetized, artificially ventilated rats were subjected to transient ischemia (30 min) by 
temporary occlusion of the left anterior descending coronary artery, followed by reperfusion (60 min) by 
removal of the arterial occlusion. Sham-operated rats were the negative controls. This model allows for 
continuous ECG monitoring of the animals and, at the end of reperfusion, appropriate cardiac tissue 
sampling for pharmacological and histopathological assays[70]. Some animals from each experimental 
group were excluded from tissue sampling and used to evaluate the area at risk, i.e., the cardiac area 
rendered ischemic by the coronary occlusion that remains unstained after an intracoronary bolus of 
methylene blue, and the infarcted area, i.e., the nonviable myocardial tissue area downstream of the 
coronary occlusion that remains unstained on incubation with the vital dye nitroblue tetrazolium[70]. 
Histaminase (DAO, EC 1.4.3.6), at the dose of 80 IU/kg b.w., given intravenously either 10 min 
before reperfusion or exactly at reperfusion, reduces the size of myocardial infarction caused by ischemia-
reperfusion. By morphometrical evaluation, the area at risk was similar in the rats subjected to ischemia-
reperfusion treated or not with histaminase, while the infarcted area, expressed as percent of the 
corresponding area at risk, was significantly reduced on histaminase administration (Fig. 5). No cardiac 
protection was afforded by semicarbazide-inactivated histaminase[70] replaced by the bioactive enzyme. 
Analysis of ECG recordings showed that histaminase reduced the occurrence of ventricular 
arrhythmias. Overall, the number of animals which survived the 60-min reperfusion was higher in the 
histaminase-treated groups than in the untreated one. Histaminase also reduced the biochemical tissue 
alterations induced by ischemia-reperfusion. In particular, MDA production (an index for peroxidation of 
cell membrane lipids by ROS), MPO activity (an index for tissue leukocyte infiltration), and calcium 
content, which were significantly elevated in the rats subjected to ischemia-reperfusion as compared with 
the sham-operated ones, were reduced by histaminase treatment. Moreover, histaminase prevented the 
activation of caspase 3, the initiator enzyme of the apoptotic cascade, induced by ischemia-reperfusion. 
In conclusion, plant histaminase appears to protect the heart from the deleterious effects of ischemia-
reperfusion[70]. The mechanisms of this effect mainly rely on histamine catabolism and removal of the 
proinflammatory and arrhythmogenic actions of this biogenic amine. In addition, histaminase may also 
act through its ROS scavenging properties. Overall, histaminase administration may offer good prospects 
for the development of new drugs to reduce the adverse effects of reperfusion in patients with acute 
coronary syndrome subjected to catheter-based angioplasty. 
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FIGURE 5. Myocardial infarction size after 30-min ischemia and 60-min reperfusion 
(IR) expressed as percent of the area-at-risk (AAR), evaluated by computer-assisted 
morphometry on nitroblue tetrazolium–stained hearts. H: histaminase (80 IU/kg b.w.), 
IH: semicarbazide-inactivated histaminase (same dose). Results are expressed as mean 
± SEM of eight experiments. 
Protective Effect of Plant Histaminase in a Rat In Vivo Model of Splanchnic 
Ischemia-Reperfusion-Induced Shock 
Splanchnic ischemia may result from different causes, leading to general or local hypoperfusion and 
impaired blood supply to the bowel[71]. Consequences of splanchnic ischemia range from persistent 
intestinal bleeding to bowel perforation and peritonitis. Thus, surgical resection of the affected bowel 
segment is usually required to minimize adverse outcomes[72]. The pathophysiology of intestinal 
ischemia has been widely investigated in animal models, mainly based on surgical occlusion of the 
splanchnic circulation followed by reperfusion (splanchnic artery occlusion/reperfusion, SAO/R). This 
results in intestinal injury and circulatory shock, with a high mortality rate[73,74]. These models permit 
investigation of the pathophysiology of SAO/R, which primarily involves endothelial dysfunction and 
leukocyte recruitment and activation, eventually leading to inflammation-mediated tissue injury. 
Histamine secretion from inflammation-activated intestinal mast cells greatly contributes to lethal 
circulatory shock occurring on SAO/R. Histamine is released by the intestinal mucosa mostly during 
reperfusion[75] and sparks a vicious cycle that leads to further endothelial activation and leukocyte 
adhesion and extravasation[76]. We have therefore investigated the therapeutic effects of pea seedling 
histaminase in a rodent model of SAO/R and circulatory shock. Anesthetized rats underwent a temporary 
(45 min) clamping of the celiac and superior mesenteric arteries near their aortic origins. Subsequent 
reperfusion was monitored for up to 6 h. Blood pressure was registered throughout the experiment. Sham-
operated animals not subjected to arterial clamping were the negative controls[77].  
Histaminase, 80 IU/kg b.w./0.5 ml of phosphate buffer, administered 15 min before reperfusion, 
significantly reduced the drop in blood pressure and high mortality rate caused by SAO/R. Histaminase 
also reduced histopathological changes, leukocyte infiltration (MPO activity), and expression of 
endothelial cell adhesion molecules in the ileum[77]. Besides reducing local tissue inflammation through 
acceleration of histamine catabolism, histaminase also seemed to counteract ROS-mediated tissue injury, 
as judged by the significant decrease in the tissue levels of peroxidation and nitration products (oxidized 
rhodamine, MDA, and nitrotyrosine), DNA damage markers (8-hydroxy-2’-deoxyguanosine and poly-
ADP-ribosylated DNA), and by consumption of tissue antioxidant enzymes, such as superoxide 
dismutase. As a result, histaminase led to a reduction in ileal cell apoptosis, as assessed by analysis of 
caspase 3 activity and of the number of TUNEL-positive cells.  
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In keeping with the findings from cardiac ischemia-reperfusion, the present study offers evidence that 
histaminase can afford protection against SAO/R-induced splanchnic injury, likely due to oxidative 
catabolism of proinflammatory histamine as well as antioxidant effects[78], resulting in hindrance of free 
radical–mediated tissue injury endothelial dysfunction and leukocyte recruitment[77]. Based on the 
above, and given that no definite medical therapy for intestinal ischemia currently exists, histaminase may 
be a possible candidate for the treatment of this disease.  
CONCLUSIONS AND PERSPECTIVES 
Histamine and other primary amines released during anaphylactic reactions undergo oxidative 
deamination by histaminase. A series of pharmacological studies from our group indicate that pea 
seedling histaminase counteracts cardiac anaphylaxis and pulmonary asthma-like reaction to aerosolized 
allergen in sensitized guinea pigs. The mechanisms by which histaminase exerts its beneficial action 
appear to consist mainly in the inactivation of endogenously released histamine and, secondly, in an 
antioxidant, ROS-scavenging action. In addition to histamine, ROS also play a key pathogenic role in 
allergic asthma and other inflammatory lung diseases, as they are harmful and responsible for cell 
dysfunction, damage, and death. Moreover, histamine and pro-oxidant species, e.g., superoxide anion, 
massively released on allergen challenge, can account for bronchospasm, vascular edema, and leukocyte 
recruitment. In our studies, treatment with pea seedling histaminase markedly decreased the adverse 
effects of cardiac and lung anaphylaxis due to allergen challenge. The absence of any direct effect on 
mast cell granule release suggests that none of the tested histaminase preparations, both free and 
immobilized on BrCN-Sepharose, produce any cytoprotective chromoglycate-like effect on mast cells.  
In the above animal models, histaminase treatment strongly decreased the tissue levels of MDA, 
nitrotyrosine, and the markers of oxidative DNA damage, strongly suggesting that this enzyme can reduce 
oxidative tissue damage induced by ROS generated during the anaphylactic reaction. This antioxidant-
like protection of plant histaminase fits well with recent data, showing that BSAO exerts an in vitro 
antioxidant effect against electrolysis-induced oxidative species and ex vivo cardioprotective action 
against oxidative injury on isolated rat heart, comparable to the cardioprotective action of authentic 
antioxidant drugs, such as mannitol or desferoxamine[78,79]. On the other hand, it should be also taken 
into account that monoamine degradation by MAO can lead to the release of ROS, which in turn are 
involved in endothelial dysfunction, vasoconstriction, and tissue damage. In this context, paradoxically, 
histaminase on one hand and MAO-A inhibitors on the other hand can have therapeutic potential, as 
recently shown in studies in which blockade of 5-HT metabolism by pargyline, a MAO-A, inhibitor, 
affords protection against cardiac ischemia-reperfusion[80]. 
In conclusion, the results of the studies summarized in this review highlight the therapeutic potential 
of plant-derived histaminase in allergic diseases and anaphylaxis, as well as its ability to inhibit 
inflammatory and ROS-mediated tissue injury due to ischemia-reperfusion. Recent progress with 
polymeric conjugates of histaminase should enhance the pharmacological profile of this enzyme, enabling 
it to be administered by alternative routes, such as aerosol, which appear to be as effective as the 
parenteral ones. 
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